Pulling SEC filings + quote and writing the call…
BMRN
BIOMARIN PHARMACEUTICAL INC
Next earnings Aug 3, 2026 (after close) · consensus $0.73 EPS, $952M rev
Last earnings +2.6% on 2026-05-04
$55.32
▲ +1.14%$54.69▼ -2.76%
over 1Y
L $49.67EODHDH $64.08
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.1%
1W-1.5%
1M+9.8%
3M-0.6%
YTD-8.0%
1Y-2.8%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 34 analysts
Buy
Rare-disease biotech with 13% revenue growth led by Voxzogo and a pristine balance sheet, now levering up for the $4.8B Amicus deal.
Sources: SEC EDGAR (CIK 0001048477, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:48:40 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.